Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

inotuzumab ozogamicin

(ih-noh-TOO-zoo-mab OH-zoh-ga-MIH-sin)
A drug used to treat adults and children aged 1 year and older with B-cell acute lymphoblastic leukemia that is CD22 positive (expresses the protein CD22). It is used in patients whose cancer came back or did not get better with other treatment. It is also being studied in the treatment of other types of cancer. Inotuzumab ozogamicin contains a monoclonal antibody that binds to CD22, which is found on some leukemia cells. It also contains an anticancer drug, which may help kill cancer cells. Inotuzumab ozogamicin is a type of antibody-drug conjugate. Also called Besponsa.
More Information
Search NCI's Dictionary of Cancer Terms